Citizens Reiterates Market Outperform on Acrivon Therapeutics, Maintains $13 Price Target
Citizens analyst Silvan Turkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and maintains $13 price target.

Last updated: 2026-11-19 06:32:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Acrivon Therapeutics, Inc. (ACRV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.55, with a market capitalization of $61.36M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.27 to $3.56. This page covers its latest market performance, valuation, price trends and company information.
$61.36M | |
$1.44 | |
$1.60 | |
$1.42 | |
$1.43 | |
497.91K | |
259.78K | |
-- | |
$3.56 | |
$1.27 | |
-- | |
2026-06-30 |
Acrivon Therapeutics, Inc. (ACRV) last closed at $1.55 as of 2026-11-19 00:57:00, up 8.39% ($0.12) from the previous close of $1.43.
During the latest regular trading session, ACRV traded between $1.42 and $1.60, with a volume of 497.91K shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Acrivon Therapeutics, Inc. (ACRV) moved from $1.57 to $1.55, representing a decline of 1.27% ($0.02).
The stock traded between $1.39 and $1.65 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 317.02 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 12.2%
ACRV is currently trading at $1.55, placing it 12.2% of the way from its 52-week low of $1.27 to its 52-week high of $3.56. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 76 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Acrivon Therapeutics, Inc. and ACRV stock.
Citizens analyst Silvan Turkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and maintains $13 price target.
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.46) by 8.7 percent. This is a 10.64 percent increase over losses of $(0.47) per share
Eligible investors can buy real shares of Acrivon Therapeutics, Inc. (ACRV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ACRV, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ACRV shares and USD.
ACRV Shares to USD
1.00 ACRV shares = 1.55 USD
Calculations are estimates based on the latest available price and are for reference only.